The two online portals hosted through the Indian Medical Research Council (ICMR) online page will be a repository of all data on vaccine progression in India. You can access the online page from here.
“Everyone will have access to this online portal to see all recent data similar to studies, progression and clinical trials on these vaccines,” Vardhan said at the ICMR Centennial Chronology Press Convention.
Introducing the new exhibits, Vardhan said: “ICMR has been at the forefront of fitness studies in the country and now leads the country in the fight against the unprecedented pandemic through clinical rigor and innovation. It has made a massive contribution to the well – being from national exhibitions, other people will be proud to know the contributions of CIMR and the country in the field of medical sciences. “
While stressing the importance of complicated and transparent data on the state of vaccine progression, he said: “The portal provides useful and similar data to vaccine progression, ongoing clinical trials and progress in this domain at local and global levels at normal intervals. at the time of COVID, the progression of the vaccine is being strictly monitored. Therefore, it is about providing the status of vaccine progression in the country. “
Previous reports recommend that, initially, the ICMR vaccine portal will reflect data on the progression of the Covid-19 vaccine in India, however, over time, the Internet portal will be strengthened with the knowledge that will be gained on all vaccines used to save you diseases. .
“ICMR has tried to respond to the developing demands of clinical progress in biomedical studies on the one hand, and the desire to find practical answers to the country’s fitness problems, on the other hand,” reads on the portal.
Vardhan at the press convention praised ICMR’s efforts and contributions in the field of science. “It is an honor for me to publish a 100-year chronology of CIMR’s history on its premises. The contributions of the scientists related to it are commemorated and serve as an inspiration to long-term scientists,” the minister added.
On India’s pandemic combat, the Union minister added: “India’s continued emerging recovery rate and the progressive decline in case mortality have shown good luck with the COVID-19 containment strategy followed in all states and UT. From having 1 lab to more than 1,800 laboratories today, we have come a long way in building our capacity. Fortunately, we have increased our testing capacity to 15 lakh of testing. “
India is lately in stages of clinical trials of 3 Covid-19 vaccines.
Phase III or the final level of the Covid-19 Covishield vaccine clinical trial, most recently in progression through the University of Oxford and manufactured through the Serum Institute of India (SII), began Monday at the state-run Sassoon General Hospital. Pune, Maharashtra, said a senior official.
The Covishield vaccine will be given in doses to between 150 and 200 volunteers, one official said.
Indian native vaccine developers Bharat Biotech International Ltd.
Currently, the government of Uttar Pradesh has announced that the phase 3 trial of the COVAXIN coronavirus vaccine ‘COVAXIN’ will begin in Lucknow and Gorakhpur from October.
In addition, the Indian vaccine manufacturer recently announced a licensing agreement with the University of Washington School of Medicine in the United States for a single-dose intranasal vaccine opposed to covid-19 based on a new chimpanzee adenovirus. the right to distribute the vaccine in all markets in the United States, Japan and Europe, Mint reported.
As a component of the pact, Phase I trials will be conducted at the university’s vaccine and remedy evaluation unit, while Bharat Biotech will adopt additional clinical trials in India and large-scale vaccine production at its Genome Valley plant in Hyderabad.
SII has also begun production of a Covid-19 candidate vaccine developed through Codagenix Inc. , the U. S. biotechnology company said in a statement.
Nicknamed CDX-005, the coronavirus vaccine candidate has completed preclinical animal studies. The drug manufacturer aims to launch a Phase I clinical trial of its COVID-19 vaccine in the UK until the end of this year.
Meanwhile, Serum CEO Adar Poonawalla called the distribution of a Covid-19 vaccine to India’s 1. 3 billion people “a challenge of concern,” said the government would possibly want 80 billion rupees over the next year to distribute the covid-19 vaccine to people. . India.
Click here to read that Mint ePapermint is now on Telegram. Join the mint channel in your telegram and updated
Log in to our to save your favorites. It’ll only take a moment.
Your query has expired, reconnect.
You are now subscribed to our newsletters. If you can’t find any email from us, check your spam folder.